Tumor Markers for Breast Cancer: Current Utilities and Future Prospects

Aasmundstad, 1990, DNA ploidy in intraductal breast carcinomas, Eur J Cancer, 26, 956, 10.1016/0277-5379(90)90619-5 Allred, 1993, Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer, J Natl Cancer Inst, 85, 200, 10.1093/jnci/85.3.200 Allred, 1992, Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer, Hum Pathol, 23, 974, 10.1016/0046-8177(92)90257-4 Allred, 1992, HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma, J Clin Oncol, 10, 599, 10.1200/JCO.1992.10.4.599 Andry, 1989, Relation between estrogen receptor concentration and clinical and histological factors: Their relative prognostic importance after radical mastectomy for primary breast cancer, Eur J Cancer, 25, 319, 10.1016/0277-5379(89)90025-4 Bartkova, 1990, Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ, Hum Pathol, 21, 1164, 10.1016/0046-8177(90)90154-W Beatson, 1896, On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases, Lancet, 2, 104, 10.1016/S0140-6736(01)72307-0 Benz, 1992, Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu, Breast Cancer Res Treat, 24, 85, 10.1007/BF01961241 Borg, 1990, HER-2/neu amplification predicts poor survival in node-positive breast cancer, Cancer Res, 50, 4332 Borresen, 1992, Screening for germ line P53 mutations in breast cancer patients, Cancer Res, 52, 3234 Bosari, 1992, Microvessel quantitation and prognosis in invasive breast carcinoma, Hum Pathol, 23, 755, 10.1016/0046-8177(92)90344-3 Boyages, 1990, Early breast cancer: Predictors of breast recurrence for patients treated with conservative surgery and radiation therapy, Radiother Oncol, 19, 29, 10.1016/0167-8140(90)90163-Q Byrne, 1987, The use of monoclonal antibodies for the histopathological detection of mammary axillary micrometastases, Eur J Surg Oncol, 13, 409 Carney, 1991, Detection and quantitation of the neu oncoprotein, Journal of Tumor Marker Oncology, 6, 53 Cardoso de Almeida, 1992, Immunohistochemical markers in the identification of metastatic breast cancer, Breast Cancer Res Treat, 21, 201, 10.1007/BF01975003 Clark, 1988, Steroid receptors and other prognostic factors in primary breast cancer, Semin Oncol, 15, 20 Clarke, 1992, Identification of patients who are at high risk for locoregional breast cancer recurrence after conservative surgery and radiotherapy: A review article for surgeons, pathologists, and radiation and medical oncologists, J Clin Oncol, 10, 474, 10.1200/JCO.1992.10.3.474 Colomer, 1989, Circulating CA15-3 levels in the postsurgical follow-up of breast cancer patients and in nonmalignant diseases, Breast Cancer Res Treat, 13, 123, 10.1007/BF01806524 Coon, 1988, Interinstitutional variability in DNA flow cytometric analysis of tumors: The National Cancer Institute’s flow cytometry network experience, Cancer, 61, 126, 10.1002/1097-0142(19880101)61:1<126::AID-CNCR2820610122>3.0.CO;2-5 Cote, 1991, Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases, J Clin Oncol, 9, 1749, 10.1200/JCO.1991.9.10.1749 Deamaley, 1991, Micrometastases in breast cancer: Long-term follow-up of the first patient cohort, Eur J Cancer, 27, 236, 10.1016/0277-5379(91)90504-7 Delsol, 1984, Human lymphoid cells express epithelial membrane antigen, Lancet, 2, 1124, 10.1016/S0140-6736(84)91558-7 Duffy, 1988, Tissue-type plasminogen activator, a new prognostic marker in breast cancer, Cancer Res, 48, 1348 Dupont, 1985, Risk factors for breast cancer in women with proliferative breast disease, N Engl J Med, 312, 146, 10.1056/NEJM198501173120303 1992, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women, Lancet, 339, 1 Eddy, 1989, Screening for breast cancer, Ann Intern Med, 111, 389, 10.7326/0003-4819-111-5-389 Eddy, 1988, The value of mammography screening in women under age 50 years, JAMA, 259, 1512, 10.1001/jama.1988.03720100030034 Elledge, 1992, Prognostic factors in breast cancer, Semin Oncol, 19, 244 Fisher, 1991, Significance of ipsilateral breast tumour recurrence after lumpectomy, Lancet, 338, 327, 10.1016/0140-6736(91)90475-5 Fisher, 1978, Detection and significance of occult axillary node metastases in patients with invasive breast cancer, Cancer, 42, 2025, 10.1002/1097-0142(197810)42:4<2025::AID-CNCR2820420452>3.0.CO;2-J Fletcher, 1992, The breast is close to the heart, Ann Intern Med, 117, 969, 10.7326/0003-4819-117-11-969 Foekens, 1990, Prediction of relapse and survival in breast cancer patients by pS2 protein status, Cancer Res, 50, 3832 Fowble B: Ductal carcinoma in situ: Evaluation of treatment options. Educational Symposia, American Society of Clinical Oncology 29th Annual Meeting, Orlando, 1993, pp 73–79 Gribben, 1991, Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma, N Engl J Med, 325, 1525, 10.1056/NEJM199111283252201 Gusterson, 1992, Prognostic importance of c-erbB-2 expression in breast cancer, J Clin Oncol, 10, 1049, 10.1200/JCO.1992.10.7.1049 Hall, 1990, Linkage of early-onset familial breast cancer to chromosome 17q21, Science, 250, 1684, 10.1126/science.2270482 Hancock, 1991, A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of ris-diamminedichloroplatinum against human breast and ovarian tumor cell lines, Cancer Res, 51, 4575 Hare, 1988, Comparison of mammary serum antigen assay with mammography in patients with breast cancer, Med J Aust, 149, 402, 10.5694/j.1326-5377.1988.tb120698.x Harris, 1992, Breast cancer (first of three parts), N Engl J Med, 327, 319, 10.1056/NEJM199207303270505 Hayes, 1994, Angiogenesis and breast cancer, Hematol Oncol Clin North Am, 8, 51, 10.1016/S0889-8588(18)30187-4 Hayes, 1993, Elevated circulating HER-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer, Proc Am Soc Clin Oncol, 12, 58 Hayes, 1991, Evaluation of patients following primary therapy, 505 Hayes, 1988, CA15-3 and CEA spikes during chemotherapy for metastatic breast cancer, Proc Am Soc Clin Oncol, 7, 38a Hayes, 1991, Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: A Cancer and Leukemia Group B study, J Clin Oncol, 9, 1, 10.1200/JCO.1991.9.1.1 Hayes, 1992, Clinical applications of CA15-3, 281 Hayes, 1986, Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer, J Clin Oncol, 4, 1542, 10.1200/JCO.1986.4.10.1542 Henderson, 1990, Comprehensive management of disseminated breast cancer, Cancer, 66, 1439, 10.1002/1097-0142(19900915)66:14+<1439::AID-CNCR2820661421>3.0.CO;2-M Hitchcock, 1987, Cross reactivity of anti-epithelial membrane antigen monoclonal for reactive and neoplastic glial cells, J Neurooncol, 4, 345, 10.1007/BF00195605 Horak, 1992, Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer, Lancet, 340, 1120, 10.1016/0140-6736(92)93150-L Hull, 1983, Multiple estrogen receptor assays in human breast cancer, Cancer Res, 43, 413 Kallioniemi, 1988, Serum CA15-3 assay in the diagnosis and follow-up of breast cancer, Br J Cancer, 58, 213, 10.1038/bjc.1988.196 Kiang, 1990, Tumor marker kinetics in the monitoring of breast cancer, Cancer, 65, 193, 10.1002/1097-0142(19900115)65:2<193::AID-CNCR2820650202>3.0.CO;2-E Knight, 1977, Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer, Cancer Res, 37, 4669 Kute, 1990, The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients, Cancer, 66, 1810, 10.1002/1097-0142(19901015)66:8<1810::AID-CNCR2820660828>3.0.CO;2-0 Lagios, 1989, Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence, Cancer, 63, 618, 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J Leitzel, 1992, Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients, J Clin Oncol, 10, 1436, 10.1200/JCO.1992.10.9.1436 Li, 1982, Prospective study of a family cancer syndrome, JAMA, 247, 2692, 10.1001/jama.1982.03320440040031 Ludwig Breast Cancer Study Group, 1990, Prognostic importance of occult axillary lymph node micrometastases from breast cancers, Lancet, 335, 1565 Maigre, 1988, CA15-3 in breast cancer. Comparison with CEA (French), Seminars Hopital de Paris, 64, 9 Malkin, 1990, Germ line p53 mutations in a familial syndrome of breast cancer, Science, 255, 1233, 10.1126/science.1978757 Mansi, 1987, Micrometastases in bone marrow in patients with primary breast cancer: Evaluation as an early predictor of bone metastases, Br Med J, 295, 1093, 10.1136/bmj.295.6606.1093 Marques, 1990, Independent prognostic value of laminin receptor expression in breast cancer survival, Cancer Res, 50, 1479 Mathiesen, 1991, The prognostic value of estrogen and progesterone receptors in female breast cancer: A single center study, Acta Oncol, 30, 691, 10.3109/02841869109092441 Mazoujian, 1983, Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast: A marker of apocrine epithelium and breast carcinomas with apocrine features, Am J Pathol, 110, 105 McGuire, 1985, Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients, J Natl Cancer Inst, 75, 405 Muss HB, Thor A, Berry DA, et al: c-erfaB-2 expression and S-phase activity predict response to adjuvant therapy in women with node positive early breast cancer. N Engl J Med, in press Nguyen, 1994, Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers, J Natl Cancer Inst, 86, 356, 10.1093/jnci/86.5.356 Nicolini, 1991, Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients, Br J Cancer, 64, 154, 10.1038/bjc.1991.260 1990, Treatment of early-stage breast cancer, JAMA, 265, 391 Nomura, 1992, Cancer, 69, 153, 10.1002/1097-0142(19920101)69:1<153::AID-CNCR2820690127>3.0.CO;2-P Nyström, 1993, Breast cancer screening with mammography: Overview of Swedish randomised trials, Lancet, 341, 973, 10.1016/0140-6736(93)91067-V O’Dwyer, 1990, CEA and CA15-3 in primary and recurrent breast cancer, World J Surg, 14, 562, 10.1007/BF01658788 Osborne, 1992, Prognostic factors for breast cancer: Have they met their promise?, J Clin Oncol, 10, 679, 10.1200/JCO.1992.10.5.679 Osborne, 1991, Receptors, 301 Osborne, 1991, Breast cancer micrometastases (BMM) in bone marrow: Detection by fluorescein-labeled monoclonal antibodies (MAB) predicts early relapse, Proc Am Soc Clin Oncol, 10, 45a Perey, 1990, Elevated CA125 levels in patients with metastatic breast carcinoma, Br J Cancer, 62, 668, 10.1038/bjc.1990.353 Petrakis, 1990, Cerumen phenotype and proliferative epithelium in breast fluids of U.S.-born vs. immigrant Asian women: A possible genetic-environmental interaction, Breast Cancer Res Treat, 16, 279, 10.1007/BF01806336 Raemaekers, 1984, Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: Relation to survival, Eur J Cancer Clin Oncol, 20, 1011, 10.1016/0277-5379(84)90102-0 Recht, 1989, Therapy of in situ cancer, Hematol Oncol Clin North Am, 3, 691, 10.1016/S0889-8588(18)30527-6 Rosen, 1989, A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma, J Clin Oncol, 7, 355, 10.1200/JCO.1989.7.3.355 Ruibal, 1987, Prognostic value of CA15-3 serum levels in patients having breast cancer, Horm Metab Res, 1, 11 Sacks, 1987, Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer, Br J Cancer, 56, 820, 10.1038/bjc.1987.297 Safi, 1989, Comparison of CA15-3 and CEA in diagnosis and monitoring of breast cancer, Int J Biol Markers, 4, 207, 10.1177/172460088900400405 Sahin, 1991, Ki-67 immunostaining in node-negative Stage I/II breast carcinoma: significant correlation with prognosis, Cancer, 68, 549, 10.1002/1097-0142(19910801)68:3<549::AID-CNCR2820680318>3.0.CO;2-J Sedmak, 1989, Detection of metastatic breast carcinoma with monoclonal antibodies to cytokeratins, Arch Pathol Lab Med, 113, 786 Sedmak, 1989, Prognostic significance of cytokeratin-positive breast cancer metastases, Mod Pathol, 2, 516 Sekine, 1985, Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma, J Clin Oncol, 3, 1355, 10.1200/JCO.1985.3.10.1355 Shepard, 1991, Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic, J Clin Immunol, 11, 117, 10.1007/BF00918679 Sidransky, 1992, Inherited p53 gene mutations in breast cancer, Cancer Res, 52, 2984 Silvestrini, 1990, 3H-Thymidine-labeling index as a prognostic indicator in node-positive breast cancer, J Clin Oncol, 8, 1321, 10.1200/JCO.1990.8.8.1321 Sklar, 1991, Polymerase chain reaction: The molecular microscope of residual disease, J Clin Oncol, 9, 1521, 10.1200/JCO.1991.9.9.1521 Slamon, 1987, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Sloane, 1981, Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology, Cancer, 47, 1786, 10.1002/1097-0142(19810401)47:7<1786::AID-CNCR2820470711>3.0.CO;2-8 Smart, 1989, Factors affecting MSA levels in normal women and women with breast cancer, Aust NZ J Surg, 59, 805, 10.1111/j.1445-2197.1989.tb07013.x Stierer, 1989, Influence of early diagnosis on prognosis of recurrent breast cancer, Cancer, 64, 1128, 10.1002/1097-0142(19890901)64:5<1128::AID-CNCR2820640527>3.0.CO;2-H Strickler, 1987, Monoclonal antibodies reactive in routinely processed tissue sections of malignant lymphoma, with emphasis on T-cell lymphomas, Hum Pathol, 18, 808, 10.1016/S0046-8177(87)80055-2 Tandon, 1990, Cathepsin D and prognosis in breast cancer, N Engl J Med, 322, 297, 10.1056/NEJM199002013220504 Tandon, 1989, HER-2/neu oncogene protein and prognosis in breast cancer, J Clin Oncol, 7, 1120, 10.1200/JCO.1989.7.8.1120 Thomas, 1987, Keratins versus epithelial membrane antigen in tumor diagnosis: An immunohistochemical comparison of five monoclonal antibodies, Hum Pathol, 18, 728, 10.1016/S0046-8177(87)80244-7 Thirion B, Ricolleau G, Fumoleau P: Result of a prospective study of the CA15-3 reliability in early detection of breast cancer recurrence. Third International Workshop on Monoclonal Antibodies and Breast Cancer, Saxa Francisco, 1988 Thor, 1993, Prognostic significance of p53 overexpression in node-negative breast carcinoma: Preliminary studies support cautious optimism, J Natl Cancer Inst, 85, 176, 10.1093/jnci/85.3.176 Thor, 1988, Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow, Breast Cancer Res Treat, 11, 133, 10.1007/BF01805837 Toikkanen, 1992, Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up, J Clin Oncol, 10, 1044, 10.1200/JCO.1992.10.7.1044 Tondini, 1989, Circulating tumor markers in breast cancer, 653 Tondini, 1988, Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer, Cancer Res, 48, 4107 Trojani, 1987, Micrometastases to axillary lymph nodes from carcinoma of the breast: Detection by immunohistochemistry and prognostic significance, Br J Cancer, 55, 303, 10.1038/bjc.1987.59 van de Vijver, 1988, Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer, N Engl J Med, 319, 1239, 10.1056/NEJM198811103191902 Vogelstein, 1991, Genetic alterations in colorectal tumors, Advances in Oncology, 7, 3 Vogelstein, 1993, The multistep nature of cancer, Trends in Genetics, 9, 138, 10.1016/0168-9525(93)90209-Z Watanabe, 1992, Basic fibroblast growth factor in human serum: A prognostic test for breast cancer, Molecular Biology of the Cell, 3, 324A Weidner, 1992, Tumor angiogenesis: A new significant and independent prognostic indicator in early stage breast carcinoma, J Natl Cancer Inst, 84, 1875, 10.1093/jnci/84.24.1875 Weidner, 1991, Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma, N Engl J Med, 324, 1, 10.1056/NEJM199101033240101 Wells, 1984, The immunocytochemical detection of axillary micrometastases in breast cancer, Br J Cancer, 50, 193, 10.1038/bjc.1984.162 Wright, 1992, Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer, Br J Cancer, 65, 118, 10.1038/bjc.1992.22